Inicio>>Signaling Pathways>> Cell Cycle/Checkpoint>> c-Myc>>IRES-C11

IRES-C11

Catalog No.GC65188

IRES-C11 es un inhibidor de la traducciÓn del sitio de entrada al ribosoma interno (IRES) c-MYC espectfico. IRES-C11 bloquea la interacciÓn de un factor de acciÓn trans c-MYC IRES necesario, la ribonucleoproteÍna nuclear heterogénea A1, con su IRES. IRES-C11 no inhibe BAG-1, XIAP y p53 IRESes.

Products are for research use only. Not for human use. We do not sell to patients.

IRES-C11 Chemical Structure

Cas No.: 342416-30-2

Tamaño Precio Disponibilidad Cantidad
5mg
270,00 $
Disponible
10mg
432,00 $
Disponible
25mg
855,00 $
Disponible
50mg
1.305,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes[1][2].

IRES-C11 blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-glioblastoma properties when combined with the mechanistic target of mTOR PP242[1].IRES-C11 (50 nM) significantly inhibits both cyclin D1 and c-MYC IRES activity. IRES-C11 treatment induces a significant shift in both cyclin D1 and c-MYC mRNA to monosomal/nonribosomal fractions, whereas actin mRNA distribution is unaffected. IRES-C11 inhibits both cyclin D1 and c-MYC IRES-mediated mRNA translation, leading to reductions in protein levels.Mechanistic studies with IRES-C11 reveal binding of the inhibitors within the UP1 fragment of heterogeneous nuclear ribonucleoprotein A1.

[1]. Brent Holmes, et al. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. J Biol Chem. 2016 Jul 1;291(27):14146-14159.
[2]. Y Shi, et al. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene. 2016 Feb 25;35(8):1015-24.

Reseñas

Review for IRES-C11

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IRES-C11

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.